Hyundai Pharmaceutical현대약품

Hyundai Pharmaceutical's shares have run up sharply over the past year, while reported profitability remains thin.

Hyundai Pharmaceutical sells prescription and over-the-counter medicines, food, cosmetics and medical devices in South Korea. Trailing results to H1 2026 show revenue of about ₩202B, an operating margin of 3.5% and a net margin of 1.4%. The share price closed at ₩6,990 on 2026-10-22, up 83.2% over one year but down 21.9% over one month.

What stands out

• Revenue has grown from about ₩140B in 2021 to about ₩192B in 2025, though the path has been uneven, with a loss in 2024 and small profits in other years.
• Trailing operating income is about ₩7.0B, but trailing net income is about ₩2.8B and free cash flow is slightly negative at about -₩0.3B.
• Borrowings of about ₩49.6B exceed cash of about ₩7.7B, and liabilities are 75.5% of equity.
• Valuation is high relative to earnings: trailing P/E is 80.7 and EV/EBITDA is 25.4, compared with peers mostly in the 15 to 32 P/E range, apart from Alteogen at 83.3.
• Recent headlines tie the share rise to a US Phase 3 result for a hair-loss drug from a different company, Veradermix, which the data does not show as a Hyundai Pharmaceutical product.

What to watch

• Upcoming quarterly results and filings, as the data lists the Aug 2026 quarterly report as the latest and gives no next reporting date.
• Whether free cash flow turns positive given the current borrowings level.
• Share price volatility: the 52-week range is ₩3,500 to ₩15,960, and the stock fell 21.9% in the past month. Trading flows over the last 20 days show retail net selling and foreign net buying, with foreign ownership down from 0.8% to 0.6%.